Brenig Therapeutics has initiated the first clinical evaluation of BT-409, a brain-selective small molecule designed to inhibit the NLRP3 inflammasome in neurodegenerative diseases.

The Phase 1 single and multiple ascending dose study, expected to commence dosing in early 2026, represents a strategic approach to targeting neuroinflammation through precise molecular intervention. BT-409 was discovered and optimized using an artificial intelligence-enabled platform, with specific design parameters focused on central nervous system (CNS) penetration and pharmacokinetic properties. The Phase 1 study will evaluate BT-409’s safety, tolerability, and pharmacokinetic profile in healthy volunteers. Successful completion could enable subsequent proof-of-concept studies in multiple sclerosis and Parkinson’s disease.

Research Context

The NLRP3 inflammasome is an innate immune sensor, forming a multi-protein complex (NLRP3, ASC, pro-caspase-1) that activates caspase-1 to process pro-inflammatory cytokines IL-1β and IL-18, responding to pathogens and cellular damage. While essential for defense, its chronic activation drives numerous inflammatory diseases like gout, autoinflammatory syndromes, and neurodegenerative conditions, contributing to neuronal damage in diseases like Alzheimer’s disease, Parkinson’s, and multiple sclerosis.

Preclinical research has consistently demonstrated that targeted NLRP3 inhibition could potentially interrupt inflammatory cascades that accelerate neurodegeneration. Recent studies published in neuroinflammation journals have highlighted the mechanistic links between NLRP3 activation and progressive neural damage.

The NLRP3 inhibition space includes several clinical-stage programs. Notable competitors include Zomagen Biosciences’ VTX series, with VTX3232 completing Phase 2 studies for Parkinson’s disease; Olatec Therapeutics LLC’s dapansutrile (OLT1177), targeting gout and heart failure currently; and NodThera’s NT-0796, which produced positive Phase Ib/IIa data showing ability to reverse neuroinflammation in Parkinson’s disease.